Shengshi Tyco

Shengshi Taike is a clinical-stage biopharmaceutical company based in China that focuses on the discovery and development of innovative small molecule drugs. The company targets high-incidence diseases, particularly in the fields of metabolic disorders and oncology. Its lead candidate, Salogliptin, is a self-developed DPP-4 inhibitor that recently received marketing approval in China for the treatment of Type 2 diabetes. Shengshi Taike utilizes a proprietary drug discovery platform to maintain a diverse pipeline, including targeted therapies for solid tumors and lung cancer. The company is supported by prominent investors such as Qiming Venture Partners and IDG Capital.